样式: 排序: IF: - GO 导出 标记为已读
-
Significance of radiation therapy in the myxoid round-cell liposarcoma treatment regimen Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-24 Akiyoshi Shimatani, Hirohisa Katagiri, Hideki Murata, Junji Wasa, Michihito Miyagi, Yosuke Honda, Mitsuru Takahashi, Hiroyuki Harada, Hirofumi Asakura, Tsuyoshi Onoe
-
SlicerPIT: software development and implementation for planning and image-guided therapy in photoimmunotherapy Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-23 Takayoshi Suzuki, Satoshi Kano, Masanobu Suzuki, Seijiro Hamada, Hiroshi Idogawa, Nayuta Tsushima, Yuichi Ashikaga, Yuki Wakabayashi, Takeshi Soyama, Yasuhiro Hida, Akihiro Homma
-
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022 Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-23 Tetsuhiro Yoshinami, Kazuki Nozawa, Takamichi Yokoe, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato
-
Short- and long-term post-nephrectomy outcomes for retroperitoneal liposarcoma from a high-volume sarcoma center: a propensity score matching analysis Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-23 Guoqiang Xue, Zhen Wang, Bonan Liu, Chengpeng Li, Ang lv, Xiuyun Tian, Jianhui Wu, Hui Qiu, Chunyi Hao
-
Biomarker-oriented chemo-immunotherapy for advanced gastric cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-22 Koji Kono, Shotaro Nakajima, Kosaku Mimura
-
Clinicopathological characteristics of Lynch-like syndrome Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-20 Sakiko Nakamori, Misato Takao, Akinari Takao, Soichiro Natsume, Takeru Iijima, Ekumi Kojika, Daisuke Nakano, Kazushige Kawai, Takuhiko Inokuchi, Ai Fujimoto, Makiko Urushibara, Shin-ichiro Horiguchi, Hideyuki Ishida, Tatsuro Yamaguchi
-
New therapeutic target molecules for gastric and gastroesophageal junction cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-17 Hisato Kawakami
Molecularly targeted therapy for receptor tyrosine kinases (RTKs) has faced limitations in gastric and gastroesophageal junction (G/GEJ) cancer except for HER2-targeted agents, possibly due to inappropriate assay selection that has hindered identification of sensitive patients, in addition to coexisting genetic abnormalities as well as intratumoral heterogeneity. Immunohistochemistry of RTKs has, thus
-
A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-17 Katsumasa Nakamura, Keiji Nihei, Yoshihiro Saito, Naoto Shikama, Shin-ei Noda, Ryusuke Hara, Toshiyuki Imagumbai, Takashi Mizowaki, Takeshi Akiba, Etsuo Kunieda, Masanori Someya, Saiji Ohga, Jiro Kawamori, Takuyo Kozuka, Yosuke Ota, Koji Inaba, Takeshi Kodaira, Yoshiyuki Itoh, Kouta Funakoshi, Yoshikazu Kagami
-
Early experience and future prospects regarding use of newly developed surgical robot system, hinotori, in the field of urologic cancer surgery Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-16 Hideaki Miyake, Masato Fujisawa
-
Current status and prospects of artificial intelligence in breast cancer pathology: convolutional neural networks to prospective Vision Transformers Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-15 Ayaka Katayama, Yuki Aoki, Yukako Watanabe, Jun Horiguchi, Emad A. Rakha, Tetsunari Oyama
-
Incidence and molecular characteristics of deficient mismatch repair conditions across nine different tumors and identification of germline variants involved in Lynch-like syndrome Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-14 Tetsuya Ito, Tatsuro Yamaguchi, Kensuke Kumamoto, Okihide Suzuki, Noriyasu Chika, Satoru Kawakami, Tomonori Nagai, Tsukasa Igawa, Kenji Fujiyoshi, Yoshito Akagi, Tomio Arai, Kiwamu Akagi, Hidetaka Eguchi, Yasushi Okazaki, Hideyuki Ishida
-
English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-13 Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Takahashi, Hironobu Hashimoto, Midori Udo, Minako Araki, Sumito Nishidate
-
Progressive changes in the protein expression profile of alveolar septa in early-stage lung adenocarcinoma Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-11 Toru Kimura, Takashi Akazawa, Yu Mizote, Harumi Nakamura, Miki Sakaue, Tomohiro Maniwa, Yasushi Shintani, Keiichiro Honma, Hideaki Tahara, Jiro Okami
-
Preoperative predictive factors for positive peritoneal cytology results in patients with pancreatic ductal adenocarcinomas: a retrospective study Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-10 Gaku Shimane, Yutaka Nakano, Minoru Kitago, Hiroshi Yagi, Yuta Abe, Yasushi Hasegawa, Shigeyoshi Soga, Shigeo Okuda, Ryota Ishii, Yuko Kitagawa
-
Modified neoadjuvant rectal score as a novel prognostic model for rectal cancer patients who underwent chemoradiotherapy Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-09 Kazushige Kawai, Kosuke Ozaki, Daisuke Nakano, Akira Dejima, Ichiro Ise, Sakiko Nakamori, Hiroki Kato, Soichiro Natsume, Misato Takao, Tatsuro Yamaguchi, Soichiro Ishihara
-
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-08 Takeru Wakatsuki, Naoki Ishizuka, Shuichi Hironaka, Keiko Minashi, Shigenori Kadowaki, Masahiro Goto, Hirokazu Shoji, Hidekazu Hirano, Izuma Nakayama, Hiroki Osumi, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, Daisuke Takahari
-
Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-08 Shunsuke Owa, Takeshi Sasaki, Ryota Ikadai, Yusaku Tabata, Yushiro Takeuchi, Taketomo Nishikawa, Momoko Kato, Shinichiro Higashi, Yusuke Sugino, Satoru Masui, Kouhei Nishikawa, Takahiro Inoue
-
Development and validation of a nomogram to predict overall survival in patients with redefined anaplastic thyroid carcinoma based on the SEER database Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-07 Chuyue Zhang, Bin Li, Yan Yang
-
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-06
Abstract Background Triplet therapy, androgen receptor signaling inhibitors (ARSIs) plus docetaxel plus androgen-deprivation therapy (ADT), is a novel guideline-recommended treatment for metastatic hormone-sensitive prostate cancer (mHSPC). However, the optimal selection of the patient most likely to benefit from triplet therapy remains unclear. Methods We performed a systematic review, meta-analysis
-
MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-06 Hirotaka Nagasaka, Takeshi Kishida, Taku Kouro, Yuka Igarashi, Shinichi Takebe, Shotaro Yamamoto, Takuya Kondo, Mitsuyuki Koizumi, Hideyuki Terao, Takahisa Suzuki, Noboru Nakaigawa, Hidetomo Himuro, Feifei Wei, Tetsuro Sasada
Background Few studies have reported reliable prognostic factors for immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC). Therefore, we investigated prognostic factors in patients treated with ICIs for unresectable or metastatic RCC. Methods We included 43 patients who received ICI treatment for RCC between January 2018 and October 2021. Blood samples were drawn before treatment, and
-
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-05 Mamoru Ito, Yuta Okumura, Kenta Nio, Eishi Baba, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Kenji Tsuchihashi
Background Granulocyte colony-stimulating factor (G-CSF) reportedly reduces the risk of neutropenia and subsequent infections caused by cancer chemotherapy. Although several guidelines recommend using G-CSF in primary prophylaxis according to the incidence rate of chemotherapy-induced febrile neutropenia (FN), the effectiveness of G-CSF in digestive system tumor chemotherapy remains unclear. To address
-
Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-02 Motohiro Matsui, Atsushi Makimoto, Motoaki Chin, Katsuyoshi Koh, Masako Tomotsune, Tetsuji Kaneko, Yoshihiko Morikawa, Riku Hamada, Yuki Yuza
Background The present study aimed to examine the effect of magnesium (Mg) supplementation on cisplatin-induced nephrotoxicity (CIN) in pediatric cancer patients. Methods The present phase-2, open-label, multicenter, randomized controlled trial enrolled patients aged less than 20 years who were scheduled to receive cisplatin-containing chemotherapy and randomly allocated them at a ratio of 1:1 to a
-
Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-04-02
Abstract Background Sarcopenia and myosteatosis have been associated with a poor prognosis for several cancers. The albumin-myosteatosis gauge (AMG) is a novel integrated measure proposed to assess myosteatosis along with serum albumin level as a surrogate of systemic inflammation and malnutrition. The aim of this study was to investigate the prognostic value of AMG in patients with advanced pancreatic
-
Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-30 Sho Iwaki, Shigenori Kadowaki, Kazunori Honda, Yukiya Narita, Toshiki Masuishi, Hiroya Taniguchi, Masashi Ando, Kei Muro, Michi Sawabe, Hidenori Suzuki, Daisuke Nishikawa, Shintaro Beppu, Hoshino Terada, Toshihiro Kishikawa, Daisuke Kawakita, Nobuhiro Hanai
Background Pembrolizumab alone or combined with chemotherapy is the standard of care for first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with positive programmed death-ligand 1 combined positive scores. However, data on second-line chemotherapy following pembrolizumab are scarce. Methods A single-center, retrospective study was conducted
-
Lymphatic drainage patterns of malignant skin tumors in the head and neck region: a single-center retrospective study Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-30 Takuya Nishio, Taku Maeda, Kosuke Ishikawa, Naoki Murao, Kanako Fuyama, Yuhei Yamamoto, Toshihiko Hayashi
Background This study aimed to clarify the relationship between primary site and lymphatic drainage pattern for malignant skin tumors in the head and neck region. Malignant melanoma and squamous cell carcinoma in the head and neck region are known to have poor prognosis because of lymph node metastasis. Nevertheless, numerous aspects of lymphatic drainage patterns remain elusive. Methods We statistically
-
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-29
Abstract Circulating tumor DNA (ctDNA) is the fraction of cell-free DNA in patient blood that originates from a tumor. Advances in DNA sequencing technologies and our understanding of the molecular biology of tumors have increased interest in exploiting ctDNA to facilitate detection of molecular residual disease (MRD). Analysis of ctDNA as a promising MRD biomarker of solid malignancies has a central
-
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022 Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-28 Shoji Kimura, Keisuke Shigeta, Shingo Tamura, Keita Uchino, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato
Background Docetaxel (DTX) is commonly used as a primary chemotherapy, and cabazitaxel (CBZ) has shown efficacy in patients who are DTX resistant. Primary prophylactic granulocyte colony stimulating factor (G-CSF) therapy is currently used with CBZ treatment in routine clinical care in Japan. Methods In this study, we performed a systematic review following the Minds guidelines to investigate the effectiveness
-
MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-26 Han Byul Kang, Sung Hwan Kim, Joo Hwan Lee, Hyo Chun Lee, Nam Kyu Kang, Jong Hoon Lee
-
PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-25 João Neif Antonio Junior, Daniel D.’Almeida Preto, Maria Eduarda Zanatta Neder Lazarini, Marcos Alves de Lima, Murilo Bonatelli, Gustavo Noriz Berardinelli, Vinicius Duval da Silva, Céline Pinheiro, Rui Manuel Reis, Flavio Mavignier Cárcano
-
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-25 Della Varghese, Giovanna I. Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C. Faherty, David Harland, Henry G. Kaplan
-
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022 Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-25 Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato
-
Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-25 Chung Ryul Oh, Hyehyun Jeong, Wanlim Kim, Jong-Seok Lee, Si Yeol Song, Joon Seon Song, Kyung-Ja Cho, Hye Won Chung, Min Hee Lee, Jung Yong Hong, Jeeyun Lee, Jeong Eun Kim, Jin-Hee Ahn
-
Local excision versus radical surgery for anal squamous cell carcinoma: a multicenter study in Japan Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-25 Shin Murai, Hiroaki Nozawa, Kazutaka Yamada, Yasumitsu Saiki, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Hiroyuki Matsuzaki, Yuichiro Yokoyama, Shinya Abe, Yuzo Nagai, Yuichiro Yoshioka, Takahide Shinagawa, Hirofumi Sonoda, Kenichi Sugihara, Yoichi Ajioka, Soichiro Ishihara
-
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022 Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-22 Keita Uchino, Shingo Tamura, Shoji Kimura, Keisuke Shigeta, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato
-
Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-22 Zhimin Gao, Yubin Pang, Xu Qin, Gang Li, Zewei Wang, Lei Zhang, Junqi Wang, Nienie Qi, Hailong Li
-
Macroscopic type is implicated in the prognostic impact of initial chemotherapy on peritoneal lavage cytology-positive gastric cancer with no other noncurative factors Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-21
Abstract Background Initial chemotherapy (Initial-C) followed by surgery is a promising treatment strategy for peritoneal lavage cytology-positive gastric cancer (CY1 GC) with no other noncurative factors. The aim of this study was to investigate the survival advantage of Initial-C compared to initial surgery (Initial-S) for this disease according to the macroscopic type, which was associated with
-
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-18 Tomoya Maeda, Yuho Najima, Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miumra, Makoto Endo, Dai Maruyama, Tatsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano,
-
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2 Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-17 Yoshinori Kikuchi, Hideaki Shimada, Fumiyuki Yamasaki, Taku Yamashita, Koji Araki, Kohei Horimoto, Satoshi Yajima, Masakazu Yashiro, Keigo Yokoi, Haruhiko Cho, Takuya Ehira, Kazunari Nakahara, Hiroshi Yasuda, Kazutoshi Isobe, Tetsu Hayashida, Shingo Hatakeyama, Koichiro Akakura, Daisuke Aoki, Hiroyuki Nomura, Yuji Tada, Yuki Yoshimatsu, Hayato Miyachi, Chiaki Takebayashi, Ichiro Hanamura, Hiroyuki
In recent years, rapid advancement in gene/protein analysis technology has resulted in target molecule identification that may be useful in cancer treatment. Therefore, “Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition” was published in Japan in September 2021. These guidelines were established to align the clinical usefulness of external diagnostic products with the evaluation
-
Salivary gland-type cancers: cross-organ demographics of a rare cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-16 Aika Tanzawa, Kengo Saito, Masayuki Ota, Koji Takahashi, Izumi Ohno, Toyoyuki Hanazawa, Katsuhiro Uzawa, Yuichi Takiguchi
-
An approach for improvement of the accuracy of cancer gene panel testing Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-12 Kiyomi Imoto, Hiroyuki Yamamoto, Chie Ohkawa, Naoki Shimada, Ryo Ikuzawa, Hiroyuki Takeda, Tatsuru Ohhara, Yasuyuki Kojima, Naoki Furuya, Ai Motoyoshi, Ohsuke Migita, Asami Kuga, Takayuki Keira, Hirotake Wakamatsu, Tomoo Sato, Nobuyuki Oike, Junki Koike, Yoshihisa Yamano, Yu Sunakawa
-
Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-02 Mashio Nakamura, Masato Sakon, Mitsuru Sasako, Takuji Okusaka, Hirofumi Mukai, Keiichi Fujiwara, Hideo Kunitoh, Mari S. Oba, Hideo Wada, Jun Hosokawa, Atsushi Takita, Masataka Ikeda
-
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-03-02 Masaki Hashimoto, Wataru Fukuokaya, Takafumi Yanagisawa, Shutaro Yamamoto, Yuhei Koike, Yu Imai, Kosuke Iwatani, Hajime Onuma, Kagenori Ito, Fumihiko Urabe, Shunsuke Tsuzuki, Shoji Kimura, Yu Oyama, HIrokazu Abe, Jun Miki, Takahiro Kimura
-
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-28
Abstract Background Enfortumab vedotin is a novel antibody–drug conjugate used as a third-line therapy for the treatment of urothelial cancer. We aimed to elucidate the effect of enfortumab vedotin-related peripheral neuropathy on its efficacy and whether enfortumab vedotin-induced early electrophysiological changes could be associated with peripheral neuropathy onset. Methods Our prospective multicenter
-
Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-27
Abstract Background Thrombospondin-1 (THBS1) is a secretory adhesive glycoprotein involved in the progression of multiple malignancies, including breast cancer. However, the clinical significance and prognostic role of plasma THBS1 in breast cancer have yet to be clarified. Methods Plasma THBS1 levels in 627 breast cancer patients were analyzed by enzyme-linked immunosorbent assay. Bone marrow blood
-
Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-27 Ryoko Rikitake, Yu Mizushima, Seiichi Yoshimoto, Takahiro Higashi, Tomoyuki Satake, Chigusa Morizane, Akira Kawai
-
Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-24
Abstract Background Financial burden of cancer treatment can negatively affect patients and their families. This study aimed to evaluate the financial toxicity of patients treated with molecular-targeted and immune therapies and explore the relationship between financial toxicity and patient experiences associated with the financial burden of cancer treatment. Methods This anonymous, self-administered
-
Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-21
Abstract Background Gastric cancer (GC) is a malignant tumor with a high mortality rate, and thus, it is necessary to explore molecular mechanisms underlying its progression. While replication factor C subunit 3 (RFC3) has been demonstrated to function as an oncogene in many cancers, its role in GC remains unclear. Methods Tumor tissues were collected from clinical GC patients, and the expression of
-
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-21 Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto
-
Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021 Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-21 Hidekatsu Nakai, Takahiro Higashi, Tamaki Kakuwa, Noriomi Matsumura
-
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022 Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-14
Abstract Background Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung
-
Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-14 Junji Furuse, Fumihiko Osugi, Koji Machii, Koji Niibe, Toshimitsu Endo
-
Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-14 Shigeki Kataoka, Yoshitaka Nishikawa, Taro Funakoshi, Takahiro Horimatsu, Minoru Sakuragi, Eiichiro Uchino, Shusuke Hiragi, Shinya Yamamoto, Kaoru Sakai, Takeshi Matsubara, Motoko Yanagita, Manabu Muto
-
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-12 Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi
-
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-09 Honami Sato, Takahiro Kobayashi, Yoshihiro Kameoka, Kazuaki Teshima, Atsushi Watanabe, Masahiro Yamada, Takaya Yamashita, Shinsuke Noguchi, Yoshihiro Michisita, Naohito Fujishima, Jun Kuroki, Naoto Takahashi
-
Hydronephrosis severity as a predictor of postoperative renal function decline following laparoscopic radical nephroureterectomy Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-06 Toru Kanno, Go Kobori, Ryoichi Saito, Katsuhiro Ito, Hiromichi Nakagawa, Toshifumi Takahashi, Shigeki Koterazawa, Naoto Takaoka, Shinya Somiya, Takao Haitani, Kanji Nagahama, Masaaki Ito, Yoshihito Higashi, Seiji Moroi, Toshiya Akao, Hitoshi Yamada
-
Skeletal muscle status and survival among patients with advanced biliary tract cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-06 Shinya Takaoka, Tsuyoshi Hamada, Naminatsu Takahara, Kei Saito, Go Endo, Ryunosuke Hakuta, Kota Ishida, Kazunaga Ishigaki, Sachiko Kanai, Kohei Kurihara, Hiroki Oyama, Tomotaka Saito, Tatsuya Sato, Tatsunori Suzuki, Yukari Suzuki, Shuichi Tange, Yurie Tokito, Ryosuke Tateishi, Yousuke Nakai, Mitsuhiro Fujishiro
-
EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-06
Abstract Introduction The developments of perioperative treatments for patients with high-risk early-stage lung cancer are ongoing, however, real-world data and evidence of clinical significance of genetic aberration are lacking in this population. This study aimed to identify patients with early-stage lung adenocarcinoma at high risk for recurrence based on pathological indicators of poor prognosis
-
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-02-04 Hasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, Musa Barış Aykan, Mustafa Korkmaz, Selim Yalçın, Teoman Şakalar, Özde Melisa Celayir, Erkan Kayıkçıoğlu, Ferit Aslan, Emre Hafızoğlu, Yunus Emre Altıntaş, Merve Keskinkılıç, Elvin Chalabiyev, Abdussamet Çelebi, Bengü Dursun, Caner Kapar, Miraç Özen, Ömer Acar, Özgecan Dülgar, Engin Kut, Sedat Biter, Fatih Kus, Elvina Almuradova, Atike Pınar Erdoğan, Seray
-
Low skeletal muscle radiodensity is a risk factor for adjuvant chemotherapy discontinuation in colorectal cancer Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-01-29 Keigo Yokoi, Akiko Watanabe, Kazuko Yokota, Keita Kojima, Toshimichi Tanaka, Ken Kojo, Hirohisa Miura, Takahiro Yamanashi, Takeo Sato, Keishi Yamashita, Yusuke Kumamoto, Naoki Hiki, Takeshi Naitoh
-
Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements Int. J. Clin. Oncol. (IF 3.3) Pub Date : 2024-01-28 Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka